keyword
MENU ▼
Read by QxMD icon Read
search

Vaccine safety

keyword
https://www.readbyqxmd.com/read/28449134/characterizing-exogenous-mrna-delivery-trafficking-cytoplasmic-release-and-rna-protein-correlations-at-the-level-of-single-cells
#1
Jonathan L Kirschman, Sushma Bhosle, Daryll Vanover, Emmeline L Blanchard, Kristin H Loomis, Chiara Zurla, Kathryn Murray, Blaine C Lam, Philip J Santangelo
The use of synthetic messenger ribonucleic acid (mRNA) to express specific proteins is a highly promising therapeutic and vaccine approach that avoids many safety issues associated with viral or DNA-based systems. However, in order to optimize mRNA designs and delivery, technology advancements are required to study fundamental mechanisms of mRNA uptake and localization at the single-cell and tissue level. Here, we present a single RNA sensitive fluorescent labeling method which allows us to label and visualize synthetic mRNA without significantly affecting function...
April 26, 2017: Nucleic Acids Research
https://www.readbyqxmd.com/read/28447476/mtbvac-from-discovery-to-clinical-trials-in-tuberculosis-endemic-countries
#2
Dessislava Marinova, Jesus Gonzalo-Asensio, Nacho Aguilo, Carlos Martin
BCG remains the only vaccine against tuberculosis (TB) in use today and despite its impressive global coverage, the nature of BCG protection against the pulmonary forms of TB remains subject to ongoing debate. Because of the limitations of BCG, novel TB vaccine candidates have been developed and several have reached the clinical pipeline. One of these candidates is MTBVAC, the first and only TB vaccine in the clinical pipeline to date based on live-attenuated Mycobacterium tuberculosis that has successfully entered clinical evaluation, a historic milestone in human vaccinology...
April 27, 2017: Expert Review of Vaccines
https://www.readbyqxmd.com/read/28446740/biological-risk-among-agriculture-and-construction-workers-in-molise-region-central-italy
#3
Manuela Tamburro, Vincenza Anzelmo, Paolo Bianco, Michela Lucia Sammarco, Francesco Salierno, Giancarlo Ripabelli
BACKGROUND: Biological risk is a significant issue in workplaces due to continuous modification of work organization and condition. OBJECTIVES: In this pilot study, perception and knowledge of biological risk, as well as adoption of prevention measures were evaluated among construction and agriculture workers. METHODS: A structured questionnaire was administered to workers to collect socio-demographic and employment information, in addition to data on risk perception and knowledge, and adoption of preventive measures, including those related to work activities...
April 21, 2017: La Medicina del Lavoro
https://www.readbyqxmd.com/read/28446260/human-papillomavirus-9-valent-vaccine-for-cancer-prevention-a-systematic-review-of-the-available-evidence
#4
C Signorelli, A Odone, V Ciorba, P Cella, R A Audisio, A Lombardi, L Mariani, F S Mennini, S Pecorelli, G Rezza, G V Zuccotti, A Peracino
In 2014, the Food and Drug Administration approved a new human papillomavirus 9-valent vaccine (9vHPV), targeting nine HPV types: HPV types 6, 11, 16, and 18, which are also targeted by the quadrivalent HPV vaccine (qHPV), plus five additional high cancer risk HPV types (HPV types 31, 33, 45, 52, and 58). The aim of the current study was to systematically retrieve, qualitatively and quantitatively pool, as well as critically appraise all available evidence on 9vHPV from randomized controlled trials (RCTs). We conducted a systematic review of the literature on 9vHPV efficacy, immunogenicity and safety, as well as a systematic search of registered, completed, and ongoing RCTs...
April 27, 2017: Epidemiology and Infection
https://www.readbyqxmd.com/read/28441266/safety-of-the-inactivated-japanese-encephalitis-virus-vaccine-ixiaro%C3%A2-in-children-an-open-label-randomized-active-controlled-phase-3-study
#5
Katrin L Dubischar, Vera Kadlecek, Benjamin Sablan, Charissa Fay Borja-Tabora, Salvacion Gatchalian, Susanne Eder-Lingelbach, Zsuzsanna Mueller, Kerstin Westritschnig
BACKGROUND: Japanese encephalitis (JE) remains a serious health concern in Asian countries and has sporadically affected pediatric travelers. In the present study we monitored the safety profile of the JE virus (JEV) vaccine IXIARO in a pediatric population. METHODS: We randomized 1869 children between the age of 2 months and 17 years in an age-stratified manner to vaccination with IXIARO or one of the control vaccines, Prevnar and HAVRIX 720. Adverse events (AEs) (unsolicited and solicited local and systemic adverse events), serious AEs and medically-attended AEs were assessed up to Day 56 and Month 7 after the first dose...
April 24, 2017: Pediatric Infectious Disease Journal
https://www.readbyqxmd.com/read/28441094/background-rates-of-disease-in-latin-american-children-from-a-rotavirus-vaccine-study
#6
Marc Baay, Kaatje Bollaerts, Claudio Struchiner, Thomas Verstraeten
BACKGROUND: Knowledge of background rates of adverse events is crucial to assess vaccine safety concerns. We used data from a rotavirus vaccine study (Ruiz-Palacios et al., NEJM, 2006) including 63,225 infants from 11 Latin American countries to investigate reporting rates of serious adverse events (SAEs) among these infants, and describe rates by country, gender, age, and season. METHODS: For this randomized, double-blind, placebo-controlled, phase 3 trial, investigators from Argentina, Brazil, Chile, Colombia, Dominican Republic, Honduras, Mexico, Nicaragua, Panama, Peru, and Venezuela recruited 6-to-13-week-old healthy infants...
April 25, 2017: Human Vaccines & Immunotherapeutics
https://www.readbyqxmd.com/read/28440187/genetic-modifications-of-icosahedral-plant-virus-based-nanoparticles-for-vaccine-and-immunotherapy-applications
#7
Kannan Badri Narayanan, Sung Soo Han
Vaccine development is one of the greatest achievements of modern medicine. Vaccines made of live-attenuated pathogens can revert to virulent live strains, which causes safety concerns. On the other hand, the use of purified antigenic components as subunit vaccines is safer, but less effective, as these components induce lower levels of protective immunity. Multiple copy presentation of an antigenic determinant in a well-ordered and well-defined orientation on a nanosized particle can mimic the natural host-pathogen surface interaction to provide antigen stability and immunogenicity similar to that of conventional vaccines with improved safety...
April 24, 2017: Current Protein & Peptide Science
https://www.readbyqxmd.com/read/28438674/current-state-and-challenges-in-developing-oral-vaccines
#8
REVIEW
Julia E Vela Ramirez, Lindsey A Sharpe, Nicholas A Peppas
While vaccination remains the most cost effective strategy for disease prevention, communicable diseases persist as the second leading cause of death worldwide. There is a need to design safe, novel vaccine delivery methods to protect against unaddressed and emerging diseases. Development of vaccines administered orally is preferable to traditional injection-based formulations for numerous reasons including improved safety and compliance, and easier manufacturing and administration. Additionally, the oral route enables stimulation of humoral and cellular immune responses at both systemic and mucosal sites to establish broader and long-lasting protection...
April 21, 2017: Advanced Drug Delivery Reviews
https://www.readbyqxmd.com/read/28438410/vaccination-with-recombinant-modified-vaccinia-ankara-mva-viruses-expressing-single-african-horse-sickness-virus-vp2-antigens-induced-cross-reactive-virus-neutralising-antibodies-vnab-in-horses-when-administered-in-combination
#9
Nicola Mary Manning, Katarzyna Bachanek-Bankowska, Peter Paul Clement Mertens, Javier Castillo-Olivares
African horse sickness is a lethal viral disease of equids transmitted by biting midges of the Genus Culicoides. The disease is endemic to sub-Saharan Africa but outbreaks of high mortality and economic impact have occurred in the past in non-endemic regions of Africa, Asia and Southern Europe. Vaccination is critical for the control of this disease but only live attenuated vaccines are currently available. However, there are bio-safety concerns over the use of this type of vaccines, especially in non-endemic countries, and live attenuated vaccines do not have DIVA (Differentiation of Infected from Vaccinated Animals) capacity...
April 21, 2017: Vaccine
https://www.readbyqxmd.com/read/28438406/coverage-and-determinants-of-childhood-immunization-in-nigeria-a-systematic-review-and-meta-analysis
#10
REVIEW
Davies Adeloye, Wura Jacobs, Ann O Amuta, Oluwatomisin Ogundipe, Oluwaseun Mosaku, Muktar A Gadanya, Gbolahan Oni
INTRODUCTION: The proportion of fully immunized children in Nigeria is reportedly low. There are concerns over national immunization data quality, with this possibly limiting country-wide response. We reviewed publicly available evidence on routine immunization across Nigeria to estimate national and zonal coverage of childhood immunization and associated determinants. METHODS: A systematic search of Medline, EMBASE, Global Health and African Journals Online (AJOL) was conducted...
April 21, 2017: Vaccine
https://www.readbyqxmd.com/read/28436552/systematic-review-with-meta-analysis-the-efficacy-and-safety-of-tenofovir-to-prevent-mother-to-child-transmission-of-hepatitis-b-virus
#11
REVIEW
M H Hyun, Y-S Lee, J H Kim, J H Je, Y J Yoo, J E Yeon, K S Byun
BACKGROUND: Preventing mother to child transmission of chronic hepatitis B infection in the setting of a high maternal viral load is challenging. The idea has emerged from antepartum tenofovir treatment with combination immunoprophylaxis. AIMS: To demonstrate the efficacy and safety of tenofovir to prevent mother to child transmission of hepatitis B virus. METHODS: PubMed, EMBASE, and Cochrane databases were searched through August 16, 2016...
April 24, 2017: Alimentary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/28434944/dose-dependent-t-cell-dynamics-and-cytokine-cascade-following-rvsv-zebov-immunization
#12
Christine Dahlke, Rahel Kasonta, Sebastian Lunemann, Verena Krähling, Madeleine E Zinser, Nadine Biedenkopf, Sarah K Fehling, My L Ly, Anne Rechtien, Hans C Stubbe, Flaminia Olearo, Saskia Borregaard, Alen Jambrecina, Felix Stahl, Thomas Strecker, Markus Eickmann, Marc Lütgehetmann, Michael Spohn, Stefan Schmiedel, Ansgar W Lohse, Stephan Becker, Marylyn M Addo
BACKGROUND: The recent West African Ebola epidemic led to accelerated efforts to test Ebola vaccine candidates. As part of the World Health Organisation-led VSV Ebola Consortium (VEBCON), we performed a phase I clinical trial investigating rVSV-ZEBOV (a recombinant vesicular stomatitis virus-vectored Ebola vaccine), which has recently demonstrated protection from Ebola virus disease (EVD) in phase III clinical trials and is currently in advanced stages of licensing. So far, correlates of immune protection are incompletely understood and the role of cell-mediated immune responses has not been comprehensively investigated to date...
April 5, 2017: EBioMedicine
https://www.readbyqxmd.com/read/28431815/efficacy-and-safety-of-high-dose-influenza-vaccine-in-elderly-adults-a-systematic-review-and-meta-analysis
#13
REVIEW
Krista Wilkinson, Yichun Wei, Andrea Szwajcer, Rasheda Rabbani, Ryan Zarychanski, Ahmed M Abou-Setta, Salaheddin M Mahmud
INTRODUCTION: Older adults are prioritized for influenza vaccination but also have lowered antibody responses to the vaccine. Higher-doses of influenza antigen may increase immune response and thus be more effective. Our objectives were to compare the efficacy and safety of the high-dose influenza vaccine to the standard-dose influenza vaccine in the elderly (age>65). METHODS: Data sources: Randomized trials (RCTs) from Medline (Ovid), EMBASE (Ovid), Cochrane Library (Wiley), ClinicalTrials...
April 18, 2017: Vaccine
https://www.readbyqxmd.com/read/28431160/editorial-to-6-month-safety-data-of-ebola-zaire-vaccine-rvsv%C3%AE-g-zebov-gp-in-a-phase-iii-double-blind-placebo-controlled-randomized-study-in-healthy-adults
#14
Matthias J Schnell
No abstract text is available yet for this article.
April 18, 2017: Journal of Infectious Diseases
https://www.readbyqxmd.com/read/28429115/comparison-of-the-tolerability-of-newly-introduced-childhood-vaccines-in-the-netherlands
#15
Jeanet M Kemmeren, Nicoline At van der Maas, Hester E de Melker
In 2011, the 7-valent conjugated pneumococcal vaccine (PCV7) was replaced by the 10-valent vaccine (PCV10) and universal hepatitis B vaccination has been introduced in the Netherlands. A questionnaire study was conducted to assess the tolerability of DTaP-IPV-Hib + PCV7 (PCV7-cohort), DTaP-IPV-Hib + PCV10 (PCV10-cohort), and DTaP-IPV-Hib-HepB + PCV10 (HepB-cohort). Parents were asked to report in questionnaires local reactions and systemic adverse events (AEs) before and after vaccination of their infant at 2, 3, 4, and 11 months of age...
April 20, 2017: European Journal of Pediatrics
https://www.readbyqxmd.com/read/28428065/in-vivo-studies-investigating-biodistribution-of-nanoparticle-encapsulated-rhodamine-b-delivered-via-dissolving-microneedles
#16
Joakim Kennedy, Eneko Larrañeta, Maelíosa T C McCrudden, Cian M McCrudden, Aaron J Brady, Steven J Fallows, Helen O McCarthy, Adrien Kissenpfennig, Ryan F Donnelly
Nanoparticles (NPs) have undergone extensive investigation as drug delivery and targeting vehicles. NP delivery is often via the parenteral route, reliant on administration using hypodermic needles, which can be associated with patient compliance issues and safety concerns. In the recent past, the intradermal delivery of NPs, via novel dissolving microneedle (MN) arrays has garnered interest in the pharmaceutical community. However, published studies using this combinatorial approach have been limited, in that they have focussed on the use of in vitro and ex vivo models only...
April 17, 2017: Journal of Controlled Release: Official Journal of the Controlled Release Society
https://www.readbyqxmd.com/read/28427845/development-of-a-micro-neutralization-assay-for-ebolaviruses-using-a-replication-competent-vesicular-stomatitis-hybrid-virus-and-a-quantitative-pcr-readout
#17
Stella S Lee, Kathryn Phy, Keith Peden, Li Sheng-Fowler
Development of vaccines against highly pathogenic viruses that could also be used as agents of bioterrorism is both a public health issue and a national security priority. Methods that can quantify neutralizing antibodies will likely be crucial in demonstrating vaccine effectiveness, as most licensed viral vaccines are effective due to their capacity to elicit neutralizing antibodies. Assays to determine whether antibodies are neutralizing traditionally involve infectious virus, and the assay most commonly used is the plaque-reduction neutralization test (PRNT)...
April 17, 2017: Vaccine
https://www.readbyqxmd.com/read/28427828/a-combined-clostridium-perfringens-trueperella-pyogenes-inactivated-vaccine-induces-complete-immunoprotection-in-a-mouse-model
#18
Wenlong Zhang, Pu Wang, Bing Wang, Bo Ma, Junwei Wang
Clostridium perfringens (C. perfringens) and Trueperella pyogenes (T. pyogenes) are two bacterial pathogens frequently associated with wound infections and following lethal complications in livestock. However, prudent use of antimicrobial agents is highly required given the emergence of multidrug-resistant strains of both bacteria and need for food safety. In the current study, a combined vaccine, composed of inactivated C. perfringens and T. pyogenes, was prepared. The amount of formaldehyde being used to inactivate two bacteria was optimized to retain the immunogenicity of antigens...
April 17, 2017: Biologicals: Journal of the International Association of Biological Standardization
https://www.readbyqxmd.com/read/28425901/a-systematic-review-and-meta-analysis-for-the-adverse-effects-immunogenicity-and-efficacy-of-lyme-disease-vaccines-guiding-novel-vaccine-development
#19
Alaa Badawi, Maria Shering, Shusmita Rahman, L Robbin Lindsay
BACKGROUND: Lyme borreliosis (LB) is the most prevalent arthropod-borne infectious disease in North America. Currently, no vaccine is available to prevent LB in humans, although monovalent and multivalent vaccines have been developed in the past. OBJECTIVE: The aim of the current study is to conduct a systematic review and meta-analysis to evaluate and compare the findings from these two classes of vaccines for their reactogenicity, immunogenicity and efficacy, in the hope this may assist in the development of future vaccines...
April 20, 2017: Canadian Journal of Public Health. Revue Canadienne de Santé Publique
https://www.readbyqxmd.com/read/28425834/rift-valley-fever-vaccines-an-overview-of-the-safety-and-efficacy-of-the-live-attenuated-mp-12-vaccine-candidate
#20
Tetsuro Ikegami
Rift Valley fever (RVF) is a mosquito-borne zoonotic viral disease endemic to Africa and the Arabian Peninsula. High rates of abortion among infected ruminants and hemorrhagic fever in infected humans are major public health concerns. Commercially available veterinary RVF vaccines are important for preventing the spread of the Rift Valley fever virus (RVFV) in endemic countries; however, RVFV outbreaks continue to occur frequently in endemic countries in the 21(st) century. In the U.S., the live-attenuated MP-12 vaccine has been developed for both animal and human vaccination...
April 20, 2017: Expert Review of Vaccines
keyword
keyword
113193
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"